메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: Anticholinergics are a key element in treating neurogenic detrusor overactivity,but only limited data are available in the pediatric population, thus limitingthe application to children even for oxybutynin chloride (OC), a prototype drug. Thisretrospective study was designed to provide data regarding the efficacy, tolerability,and safety of OC in the pediatric population (0–15 years old) with spinal dysraphism(SD). Materials and Methods: Records relevant to OC use for neurogenic bladder were gatheredand scrutinized from four specialized clinics for pediatric urology. The primaryefficacy outcomes were maximal cystometric capacity (MCC) and end filling pressure(EFP). Data on tolerability, compliance, and adverse events (AEs) were also analyzed. Results: Of the 121 patient records analyzed, 41 patients (34%) received OC at less than5 years of age. The range of prescribed doses varied from 3 to 24 mg/d. The median treatmentduration was 19 months (range, 0.3–111 months). Significant improvement ofboth primary efficacy outcomes was noted following OC treatment. MCC increasedabout 8% even after adjustment for age-related increases in MCC. Likewise, mean EFPwas reduced from 33 to 21 cm H2O. More than 80% of patients showed compliance above70%, and approximately 50% of patients used OC for more than 1 year. No serious AEswere reported; constipation and facial flushing consisted of the major AEs. Conclusions: OC is safe and efficacious in treating pediatric neurogenic bladder associatedwith SD. The drug is also tolerable and the safety profile suggests that adjustmentof dosage for age may not be strictly observed.

목차

등록된 정보가 없습니다.

참고문헌 (16)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0